Deinove has selected key markets of interest, identified strains from its library of bacteria, which indicate suitability for commercial deployment, and formed partnerships to expedite that process. While uncertainties remain, commercial revenues are expected in 2018 and development of revenues in line with our projections would indicate a potential valuation of €4.4/share.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs